<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621566</url>
  </required_header>
  <id_info>
    <org_study_id>B322201835950</org_study_id>
    <nct_id>NCT03621566</nct_id>
  </id_info>
  <brief_title>Belgian Central Sleep Apnea REgistry</brief_title>
  <acronym>B-CARE</acronym>
  <official_title>Belgian Central Sleep Apnea REgistry (B-CARE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates different factors that determine the treatment choice and treatment
      compliance in patients with central sleep apnea. All patients will receive routine care
      (registry).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central sleep apnea (CSA) is characterized by intermittent cessation or decrease of airflow
      and effort of breathing during sleep. The diagnostic criteria for CSA varies according to the
      type of CSA (e.g. CSA due to cardiac failure, due to a medication, ...).

      CSA is defined as: (1) an apnea/hypopnea index ≥ 15 per hour of sleep and (2) the number of
      central apneas and/or hypopneas is &gt; 50% of the total number of apneas and hypopneas.

      Presence of CSA is associated with excessive daytime sleepiness and poor sleep quality.
      Furthermore, in patients with heart failure, presence of CSA was found to be related to
      mortality. As yet, however, there is insufficient knowledge on the clinical features,
      pathophysiological background and consecutive algorithms for treatment. Currently, it is not
      fully clear whether CSA or the treatment of CSA is related to disease progress.

      The aim of this trial is to evaluate the current treatment choices for CSA in Belgium and
      compliance with and effects of these treatments.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2018</start_date>
  <completion_date type="Anticipated">June 25, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Treatment choice</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of patients treated with the different treatment modalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors determining treatment choice</measure>
    <time_frame>5 years</time_frame>
    <description>Relation between patient and CSA characteristics and the treatment choice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>5 years</time_frame>
    <description>Compliance to the different treatment modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 Health Survey</measure>
    <time_frame>5 years</time_frame>
    <description>To measure eight domains of health
Content:
physical functioning
role limitations due to physical health
bodily pain
general health perceptions
vitality
social functioning
role limitations due to emotional problems
mental health
Number of items: 36 items are included in scoring
Score interpretation: each item scored on a 0 to 100 range so that the lower and highest possible scores are set at 0 and 100. Scores represent the percentage of total possible score achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pitssburgh Sleep Quality index</measure>
    <time_frame>5 years</time_frame>
    <description>To measure sleep quality and disturbances. Score range: 0-21 points, with lower scores indicating better sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of subjects alive with different treatment modalities</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Central Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Central Sleep Apnea</arm_group_label>
    <description>Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events &gt; 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Routine care (registry)</description>
    <arm_group_label>Central Sleep Apnea</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive
        events &gt; 50%, derived from polysomnography (diagnostic or during positive airway pressure
        treatment)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  An apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events &gt;
             50%, derived from polysomnography (diagnostic or during (PAP) treatment)

          -  Written informed consent provided

        Exclusion Criteria:

        - Patients with mental disability making it impossible to understand the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dries Testelmans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dries Testelmans, MD, PhD</last_name>
    <phone>16 342522</phone>
    <phone_ext>+32</phone_ext>
    <email>dries.testelmans@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berend-Jan Berendes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieven Bedert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Verbraecken, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle Ringoet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Bruyneel, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien Hertegonne, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolien Weytjens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Maddens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Volckaert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dries Testelmans, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Baharloo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Namur</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaut Vandenhove, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Glorieux</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwin Hill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryse Van den Heuvel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

